Karyopharm Therapeutics Inc. financial data

Symbol
KPTI on Nasdaq
Location
Newton, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 13 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 111% % -59%
Quick Ratio 4.8% % -15%
Debt-to-equity -143% % 35%
Return On Equity 78% % 65%
Return On Assets -179% % -353%
Operating Margin -62% % 24%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18,343,968 shares -85%
Common Stock, Shares, Outstanding 18,311,000 shares 118%
Entity Public Float $37,000,000 USD -66%
Common Stock, Value, Issued $14,000 USD 7.7%
Weighted Average Number of Shares Outstanding, Basic 10,935 shares 35%
Weighted Average Number of Shares Outstanding, Diluted 10,935 shares 29%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $146,067,000 USD 0.57%
Research and Development Expense $125,617,000 USD -12%
Operating Income (Loss) $90,707,000 USD 24%
Nonoperating Income (Expense) $105,289,000 USD -344%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $195,996,000 USD -157%
Income Tax Expense (Benefit) $43,000 USD -25%
Net Income (Loss) Attributable to Parent $196,039,000 USD -157%
Earnings Per Share, Basic -17.93 USD/shares -91%
Earnings Per Share, Diluted -17.93 USD/shares -28%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $60,540,000 USD -3.1%
Cash, Cash Equivalents, and Short-term Investments $63,700,000 USD
Inventory, Net $4,038,000 USD -15%
Assets, Current $103,146,000 USD -34%
Property, Plant and Equipment, Net $104,000 USD -74%
Operating Lease, Right-of-Use Asset $4,548,000 USD -23%
Assets $108,416,000 USD -34%
Accounts Payable, Current $4,003,000 USD -22%
Employee-related Liabilities, Current $4,379,000 USD -69%
Accrued Liabilities, Current $64,498,000 USD 6.3%
Liabilities, Current $92,060,000 USD -0.22%
Operating Lease, Liability, Noncurrent $5,743,000 USD -14%
Other Liabilities, Noncurrent $11,095,000 USD 357%
Liabilities $401,342,000 USD 15%
Accumulated Other Comprehensive Income (Loss), Net of Tax $71,000 USD
Retained Earnings (Accumulated Deficit) $1,759,499,000 USD -13%
Stockholders' Equity Attributable to Parent $292,926,000 USD -57%
Liabilities and Equity $108,416,000 USD -34%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $38,984,000 USD 11%
Net Cash Provided by (Used in) Investing Activities $15,288,000 USD -30%
Common Stock, Shares Authorized 53,333,000 shares 0%
Common Stock, Shares, Issued 18,311,000 shares 118%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $23,691,000 USD -8.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $60,891,000 USD -3.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities $5,135,000 USD
Deferred Tax Assets, Valuation Allowance $312,798,000 USD -30%
Deferred Tax Assets, Gross $9,039,000 USD 528%
Operating Lease, Liability $6,712,000 USD -6.1%
Depreciation $78,000 USD -8.2%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $195,612,000 USD -155%
Lessee, Operating Lease, Liability, to be Paid $9,391,000 USD -14%
Property, Plant and Equipment, Gross $5,614,000 USD -21%
Operating Lease, Liability, Current $969,000 USD 121%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,932,000 USD 2.8%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,880,000 USD 26%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,679,000 USD -28%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,985,000 USD 2.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,037,000 USD 2.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $2,803,000 USD -33%
Interest Expense $27,114,000 USD 15%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%